Safety evaluation of immunomodulatory biopharmaceuticals: can we improve the predictive value of preclinical studies?
Black
L E
LE
Center for Biologics Evaluation and Research.
Green
J D
JD
Rener
J
J
Dayan
A
A
Cavagnaro
J A
JA
Spindler
P
P
Bussiere
J L
JL
Bouchard
P
P
Inoue
T
T
Thomas
P T
PT
Essayan
D M
DM
Gillett
N A
NA
Hart
T K
TK
Hastings
K
K
House
R V
RV
Latta
D
D
Liminga
U
U
Treacy
G
G
Wierda
D
D
D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000633:toxicity*; D001702:Biopharmaceutics; D004353:Drug Evaluation, Preclinical
D000276:Adjuvants, Immunologic